Flaxseed for Hypertension: Implications for Blood Pressure Regulation

Current Hypertension Reports

Volumn 16, Issue 12, 2014, Pages 1-13

  Caligiuri, Stephanie P B ^a,b   Edel, Andrea L ^a,b   Aliani, Michel ^a,b   Pierce, Grant N ^a,b  

^a ST BONIFACE GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Alpha linolenic acid; Anti hypertensive therapy; Blood pressure regulation; Dietary flaxseed; Enterodiol; Enterolactone; Enterolignans; Lignans

Indexed keywords

ANTIHYPERTENSIVE AGENT; LIGNAN; LINOLENIC ACID;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); DIET; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERTENSION; LINSEED; META ANALYSIS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DRUG EFFECTS; FLAX; LIFESTYLE; METABOLISM; PROCEDURES;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; FLAX; HUMANS; HYPERTENSION; LIFE STYLE;

EID: 84910144862     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0499-8     Document Type: Review

References (79)

1. World Health Organization. A global brief on hypertension: silent killer, global public health crisis. WHO/DCO/WHD/2013. 2nd ed. Geneva: World Health Organization; 2013.
2. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598–605.
3. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10–7.
4. Hypertension Canada. The 2013 CHEP Recommendations. 2013. http://www.hypertension.ca/chep-recommendations. Accessed 1 May 2014.
5. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013. http://www.esh2013.org/wordpress/wp-content/uploads/2013/06/ESC-ESH-Guidelines-2013.pdf. Accessed 1 May 2014.
6. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.
7. Gebauer SK, Psota TL, Harris WS, Kris-Etherton PM. N-3 Fatty acid dietary recommendations and food sources to achieve essentiality and cardiovascular benefits. Am J Clin Nutr. 2006;83(6 Suppl):1526S–35S.
8. Prasad K. Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Int J Angiol. 2000;9(4):220–5.
9. Prasad K. Flax lignan complex slows down the progression of atherosclerosis in hyperlipidemic rabbits. J Cardiovasc Pharmacol Ther. 2009;14(1):38–48.
10. Sicilia T, Niemeyer HB, Honig DM, Metzler M. Identification and stereochemical characterization of lignans in flaxseed and pumpkin seeds. J Agric Food Chem. 2003;51(5):1181–8.
11. Carreau C, Flouriot G, Bennetau-Pelissero C, Potier M. Enterodiol and enterolactone, two major diet-derived polyphenol metabolites have different impact on ERalpha transcriptional activation in human breast cancer cells. J Steroid Biochem Mol Biol. 2008;110(1–2):176–85.
12. Bassett CM, Rodriguez-Leyva D, Pierce GN. Experimental and clinical research findings on the cardiovascular benefits of consuming flaxseed. Appl Physiol Nutr Metab. 2009;34(5):965–74.
13. Austria JA, Richard MN, Chahine MN, Edel AL, Malcolmson LJ, Dupasquier CM, et al. Bioavailability of alpha-linolenic acid in subjects after ingestion of three different forms of flaxseed. J Am Coll Nutr. 2008;27(2):214–21.
14. Kuijsten A, Arts IC, van't Veer P, Hollman PC. The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed. J Nutr. 2005;135(12):2812–6.
15. Talom RT, Judd SA, McIntosh DD, McNeill JR. High flaxseed (linseed) diet restores endothelial function in the mesenteric arterial bed of spontaneously hypertensive rats. Life Sci. 1999;64(16):1415–25.
16. Sekine S, Sasanuki S, Aoyama T, Takeuchi H. Lowering systolic blood pressure and increases in vasodilator levels in SHR with oral alpha-linolenic acid administration. J Oleo Sci. 2007;56(7):341–5.
17. Park JB, Velasquez MT. Potential effects of lignan-enriched flaxseed powder on bodyweight, visceral fat, lipid profile, and blood pressure in rats. Fitoterapia. 2012;83(5):941–6.
18. Prasad K. Secoisolariciresinol diglucoside (SDG) isolated from flaxseed, an alternative to ACE inhibitors in the treatment of hypertension. Int J Angiol. 2013;22(4):235–8.
19. Prasad K. Antihypertensive activity of secoisolariciresinol diglucoside (SDG) isolated from flaxseed: role of guanylate cyclase. Int J Angiol. 2004;13:7–14.
20. Setchell KDR, Brown NM, Zimmer-Nechemias L, Wolfe B, Jha P, Heubi JE. Metabolism of secoisolariciresinol-diglycoside the dietary precursor to the intestinally derived lignan enterolactone in humans. Food Funct. 2014;5(3):491–501.
21. Doyen A, Udenigwe CC, Mitchell PL, Marette A, Aluko RE, Bazinet L. Anti-diabetic and antihypertensive activities of two flaxseed protein hydrolysate fractions revealed following their simultaneous separation by electrodialysis with ultrafiltration membranes. Food Chem. 2014;145:66–76. This paper is of importance because of the potential for clinical impact and the insight it provides for potential mechanisms of action of flaxseed. Bioactive peptides and food sources rich in arginine including flaxseed are an exciting area of research for hypertension treatment. Bioactive peptides have the ability to inhibit Angiotensin-converting enzyme and arginine is a precursor to the vasodilator nitric oxide. The study was well designed and lays the foundation for future clinical research on flaxseed protein.
22. Udenigwe CC, Adebiyi AP, Doyen A, Li H, Bazinet L, Aluko RE. Low molecular weight flaxseed protein-derived arginine-containing peptides reduced blood pressure of spontaneously hypertensive rats faster than amino acid form of arginine and native flaxseed protein. Food Chem. 2012;132:468–75.
23. Rodriguez-Leyva D, Weighell W, Edel AL, Lavallee R, Dibrov E, Pinneker R, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension. 2013;62(6):1081–9. This paper is of major importance to the area of flaxseed and hypertension due to its study design, duration, and clinical impact. The Flax-PAD trial was a one year randomized, double-blinded, controlled trial with 110 participants. The findings indicated that consumption of flaxseed in patients with hypertension caused a reduction in blood pressure more significant than the standard dose of anti-hypertensive medication and comparable or better than any other dietary intervention. This paper has increased the awareness of flaxseed as an effective anti-hypertensive treatment.
24. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
25. Caligiuri SP, Penner B, Pierce GN. The HYPERFlax trial for determining the anti-HYPERtensive effects of dietary flaxseed in newly diagnosed stage 1 hypertensive patients: study protocol for a randomized, double-blinded, controlled clinical trial. Trials. 2014;15:232.
26. Berry EM, Hirsch J. Does dietary linolenic acid influence blood pressure? Am J Clin Nutr. 1986;44(3):336–40.
27. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994;343(8911):1454–9.
28. Ueshima H, Stamler J, Elliott P, Chan Q, Brown IJ, Carnethon MR, et al. Food omega-3 fatty acid intake of individuals (total, linolenic acid, long-chain) and their blood pressure: INTERMAP study. Hypertension. 2007;50(2):313–9.
29. Takeuchi H, Sakurai C, Noda R, Sekine S, Murano Y, Wanaka K, et al. Antihypertensive effect and safety of dietary alpha-linolenic acid in subjects with high-normal blood pressure and mild hypertension. J Oleo Sci. 2007;56(7):347–60.
30. Paschos GK, Magkos F, Panagiotakos DB, Votteas V, Zampelas A. Dietary supplementation with flaxseed oil lowers blood pressure in dyslipidaemic patients. Eur J Clin Nutr. 2007;61(10):1201–6.
31. Spence JD, Thornton T, Muir AD, Westcott ND. The effect of flax seed cultivars with differing content of α-linolenic acid and lignans on responses to mental stress. J Am Coll Nutr. 2003;22(6):494–501.
32. Cornish SM, Chilibeck PD, Paus-Jennsen L, Biem HJ, Khozani T, Senanayake V, et al. A randomized controlled trial of the effects of flaxseed lignan complex on metabolic syndrome composite score and bone mineral in older adults. Appl Physiol Nutr Metab. 2009;34(2):89–98.
33. Billinsky J, Glew RA, Cornish SM, Whiting SJ, Thorpe LU, Alcorn J, et al. No evidence of hypoglycemia or hypotension in older adults during 6 months of flax lignan supplementation in a randomized controlled trial: a safety evaluation. Pharm Biol. 2013;51(6):778–82.
34. Mazza G, Oomah B. Flaxseed, dietary fiber and cyanogens. In: Cunnane S, Thompson L, editors. Flaxseed in human nutrition. Champaign: AOCS Press; 1995. p. 56–81.
35. Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens. 2005;23(3):475–81.
36. Streppel MT, Arends LR, van’t Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med. 2005;165(2):150–6.
37. Thakur G, Mitra A, Pal K, Rousseau D. Effect of flaxseed gum on reduction of blood glucose and cholesterol in type 2 diabetic patients. Int J Food Sci Nutr. 2009;60 Suppl 6:126–36.
38. Caligiuri SP, Aukema HM, Ravandi A, Guzman R, Dibrov E, Pierce GN. Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an alpha-linolenic acid-induced inhibition of soluble epoxide hydrolase. Hypertension. 2014;64(1):53–9. This paper is the first to determine a mechanism of action for the anti-hypertensive properties of flaxseed in humans. Identifying the mechanism is critical for the generation of further confidence in the anti-hypertensive effects of dietary flaxseed. It also emphasizes the potential importance of both oxylipins and soluble epoxide hydrolase as targets for future anti-hypertensive therapy.
39. Zhao G, Etherton TD, Martin KR, Gillies PJ, West SG, Kris-Etherton PM. Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr. 2007;85(2):385–91.
40. Caligiuri SP, Aukema HM, Ravandi A, Pierce GN. Elevated levels of pro-inflammatory oxylipins in older subjects are normalized by flaxseed consumption. Exp Gerontol. 2014.
41. Puddu P, Puddu GM, Zaca F, Muscari A. Endothelial dysfunction in hypertension. Acta Cardiol. 2000;55(4):221–32.
42. Montezano AC, Touyz RM. Molecular mechanisms of hypertension—reactive oxygen species and antioxidants: a basic science update for the clinician. Can J Cardiol. 2012;28(3):288–95.
43. Hu C, Yuan YV, Kitts DD. Antioxidant activities of the flaxseed lignan secoisolariciresinol diglucoside, its aglycone secoisolariciresinol and the mammalian lignans enterodiol and enterolactone in vitro. Food Chem Toxicol. 2007;45(11):2219–27.
44. Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU. Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem. 1999;202(1–2):91–100.
45. Vanharanta M, Voutilainen S, Nurmi T, Kaikkonen J, Roberts LJ, Morrow JD, et al. Association between low serum enterolactone and increased plasma F2-isoprostanes, a measure of lipid peroxidation. Atherosclerosis. 2002;160(2):465–9.
46. Wang W, Liu LQ, Higuchi CM, Chen H. Induction of NADPH:quinone reductase by dietary phytoestrogens in colonic colo205 cells. Biochem Pharmacol. 1998;56(2):189–95.
47. Marin E, Sessa WC. Role of endothelial-derived nitric oxide in hypertension and renal disease. Curr Opin Nephrol Hypertens. 2007;16(2):105–10.
48. Seppo L, Jauhiainen T, Poussa T, Korpela R. A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. AJCN. 2003;77(2):326–30.
49. Ander BP, Weber AR, Rampersad PP, Gilchrist JS, Pierce GN, Lukas A. Dietary flaxseed protects against ventricular fibrillation induced by ischemia-reperfusion in normal and hypercholesterolemic rabbits. J Nutr. 2004;134(12):3250–6.
50. Bassett CM, McCullough RS, Edel AL, Patenaude A, LaVallee RK, Pierce GN. The alpha-linolenic acid content of flaxseed can prevent the atherogenic effects of dietary trans fat. Am J Physiol Heart Circ Physiol. 2011;301(6):H2220–6.
51. Dupasquier CM, Dibrov E, Kneesh AL, Cheung PK, Lee KG, Alexander HK, et al. Dietary flaxseed inhibits atherosclerosis in the LDL receptor-deficient mouse in part through antiproliferative and anti-inflammatory actions. Am J Physiol Heart Circ Physiol. 2007;293(4):H2394–402.
52. Abuelgassim A. Effect of flax seeds and date palm leaves extracts on serum concentrations of glucose and lipids in alloxan diabetic rats. Pak J Biol Sci. 2010;13(23):1141–5.
53. Francis AA, Deniset JF, Austria JAM, Lavallee RK, Maddaford GG, Hedley TE, et al. The effects of dietary flaxseed on atherosclerotic plaque regression. Am J Physiol Heart Circ Physiol. 2013;304(12):H1743–51.
54. Prim CR, Baroncini LA, Precoma LB, Caron PH, Winter G, Poletti MO, et al. Effects of linseed consumption for a short period of time on lipid profile and atherosclerotic lesions in rabbits fed a hypercholesterolaemic diet. Br J Nutr. 2012;107(5):660–4.
55. Haliga R, Mocanu V, Oboroceanu T, Stitt PA, Luca VC. The effects of dietary flaxseed supplementation on lipid metabolism in streptozotocin-induced diabetic hamsters. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi. 2007;111(2):472–6.
56. Jackevicius CA, Cox JL, Carreon D, Tu JV, Rinfret S, So D, et al. Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ. 2009;181(1–2):E19–28.
57. United States Food and Drug Administration. Drugs: savings from generic drugs purchased at retail pharmacies. 2009. http://www.fda.gov/drugs/resourcesforyou/ucm134205.htm. Accessed 22 Jul 2014.
58. Food and Agriculture Organization of the United Nations. Linseed. 2014. http://faostat3.fao.org/faostat-gateway/go/to/search/flaxseed/E. Accessed 1 Jun 2014.
59. The World Bank Group. The World Bank: income levels. 2013. https://wdronline.worldbank.org/worldbank/a/incomelevel Accessed 4 Jun 2014.
60. International Food Information Council. Functional foods consumer survey. 2013. http://www.foodinsight.org/2013_Functional_Foods_Consumer_Survey. Accessed 10 Jun 2014.
61. Lorig KR, Sobel DS, Stewart AL, Brown Jr BW, Bandura A, Ritter P, et al. Evidence suggesting that a chronic disease self-management program can improve health status while reducing hospitalization: a randomized trial. Med Care. 1999;37(1):5–14.
62. Food and Drug Act. GRAS Notice 000280: whole and milled flaxseed. 2009. Available at: http://www.accessdata.fda.gov/scripts/fcn/gras_notices/grn000280.pdf.
63. Health Canada. Summary of health Canada’s assessment of a health claim about ground whole flaxseed and blood cholesterol lowering. 2014. http://www.hc-sc.gc.ca.proxy2.lib.umanitoba.ca/fn-an/label-etiquet/claims-reclam/assess-evalu/flaxseed-graines-de-lin-eng.php. Accessed 30 May 2014.
64. King DE, Mainous 3rd AG, Lambourne CA. Trends in dietary fiber intake in the United States, 1999–2008. J Acad Nutr Diet. 2012;112(5):642–8.
65. Institute of Medicine. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. 2002. http://www.iom.edu/Reports/2002/Dietary-Reference-Intakes-for-Energy-Carbohydrate-Fiber-Fat-Fatty-Acids-Cholesterol-Protein-and-Amino-Acids.aspx. Accessed 12 May 2014.
66. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.
67. Rallidis LS, Paschos G, Liakos GK, Velissaridou AH, Anastasiadis G, Zampelas A. Dietary alpha-linolenic acid decreases C-reactive protein, serum amyloid A and interleukin-6 in dyslipidaemic patients. Atherosclerosis. 2003;167(2):237–42.
68. Bloedon LT, Balikai S, Chittams J, Cunnane SC, Berlin JA, Rader DJ, et al. Flaxseed and cardiovascular risk factors: results from a double blind, randomized, controlled clinical trial. J Am Coll Nutr. 2008;27(1):65–74.
69. Begg DP, Sinclair AJ, Stahl LA, Premaratna SD, Hafandi A, Jois M, et al. Hypertension induced by [omega]-3 polyunsaturated fatty acid deficiency is alleviated by [alpha]-linolenic acid regardless of dietary source. Hypertens Res. 2012;33(8):808–13.
70. Begg DP, Sinclair AJ, Stahl LA, Garg ML, Jois M, Weisinger RS. Dietary protein level interacts with ω-3 polyunsaturated fatty acid deficiency to induce hypertension. Am J Hypertens. 2010;23(2):125–8.
71. Ogawa A, Suzuki Y, Aoyama T, Takeuchi H. Dietary alpha-linolenic acid inhibits angiotensin-converting enzyme activity and mRNA expression levels in the aorta of spontaneously hypertensive rats. J Oleo Sci. 2009;58(7):355–60.
72. Wu H, Pan A, Yu Z, Qi Q, Lu L, Zhang G, et al. Lifestyle counseling and supplementation with flaxseed or walnuts influence the management of metabolic syndrome. J Nutr. 2010;140(11):1937–42.
73. Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B. The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double-blind, wheat germ placebo-controlled clinical trial. J Clin Endocrinol Metab. 2005;90(3):1390–7.
74. Stuglin C, Prasad K. Effect of flaxseed consumption on blood pressure, serum lipids, hemopoietic system and liver and kidney enzymes in healthy humans. J Cardiovasc Pharmacol Ther. 2005;10(1):23–7.
75. West SG, Krick AL, Klein LC, Zhao G, Wojtowicz TF, McGuiness M, et al. Effects of diets high in walnuts and flax oil on hemodynamic responses to stress and vascular endothelial function. J Am Coll Nutr. 2010;29(6):595–603.
76. Nestel PJ, Pomeroy SE, Sasahara T, Yamashita T, Liang YL, Dart AM, et al. Arterial compliance in obese subjects is improved with dietary plant n-3 fatty acid from flaxseed oil despite increased LDL oxidizability. Arterioscler Thromb Vasc Biol. 1997;17(6):1163–70.
77. Barre DE, Mizier-Barre KA, Stelmach E, Hobson J, Griscti O, Rudiuk A, et al. Flaxseed lignan complex administration in older human type 2 diabetics manages central obesity and prothrombosis—an invitation to further investigation into polypharmacy reduction. J Nutr Metab. 2012;2012:585170.
78. Pan A, Sun J, Chen Y, Ye X, Li H, Yu Z, et al. Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial. PLoS One. 2007;2(11):e1148.
79. Hallund J, Tetens I, Bugel S, Tholstrup T, Bruun JM. The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women. Nutr Metab Cardiovasc Dis. 2008;18(7):497–502.